Conference Track

HIV Highlights From ICAAC

Source: CCO Independent Conference Coverage of the 2007 Interscience Conference on Antimicrobial Agents and Chemotherapy*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Enhanced Phenotypic Tropism Assay Able to Detect X4 Minor Variants Within Dual/Mixed HIV Population
High Incidence of Non-AIDS– and Non-HAART–Related Events Led by Bacterial Infections in a French Cohort Followed in the HAART Era
ARTEMIS: Darunavir/Ritonavir Noninferior to Lopinavir/Ritonavir as First-Line PI in Antiretroviral-Naive HIV-Infected Patients at 48 Weeks
INTERSTART Proof-of-Concept Study: HAART Initiation Deferred by Periodic Interleukin-2 Administration in Asymptomatic HIV-Infected Patients
Untreated Individuals Chronically Infected With Dual/Mixed- vs CCR5-Tropic Virus Demonstrate Faster Disease Progression
Improvements in Lipid Parameters Following Treatment Interruption Modest and Overshadowed by Proinflammatory Changes
Switching Stavudine for Tenofovir Maintains Virologic Suppression and Immunologic Improvement, Produces Improvements in Limb Fat and Lipids
Darunavir/Ritonavir Plus Enfuvirtide Combination Results in Potent Responses in Triple-Class–Experienced Patients Regardless of Baseline Darunavir Susceptibility
Raltegravir Plus Optimized Background Regimen Yields Durable Virologic Suppression Through 48 Weeks in Heavily Treatment–Experienced Patients in Phase II Study
Elvitegravir/Ritonavir Therapy Associated With Strong, Sustained Virologic Response When Combined With at Least 1 Other Active Agent
MOTIVATE Data Suggest Majority of Cases of Treatment Failure on Maraviroc Associated With Outgrowth of Dual/Mixed-Tropic or X4 Virus From Minority Baseline Populations, With Reversion to R5 HIV After Maraviroc Discontinuation
Novel CCR5 Inhibitor, PRO 140, Well Tolerated Among Asymptomatic HIV-Infected Patients and Demonstrates Strong, Dose-Dependent Antiviral Activity
Pooled Interim Analysis of DUET-1 and -2 Data Demonstrate Potent Antiretroviral Activity of Etravirine in Treatment-Experienced Patients
Final 48-Week MOTIVATE 1 Data Confirm Potent, Durable Antiretroviral Activity Associated With Maraviroc Therapy in Treatment-Experienced Patients
Higher Incidence of Non-AIDS–Defining Malignancies in HIV-Infected Veterans vs HIV-Uninfected Veterans
Long-term Treatment With Vicriviroc Associated With Durable Virologic Efficacy and Immune Preservation in Treatment-Experienced Patients
TITAN: Darunavir’s High Genetic Barrier to Resistance May Preserve Future Treatment Options in Moderately Treatment–Experienced Patients
STACCATO Data Indicate Structured Treatment Interruption in HIV/HBV-Coinfected Patients Can Lead to HBV Viremia and Transaminase Elevations
NNRTI-Based, but Not PI-Based, HAART Significantly Associated With Slower Rate of Fibrosis Progression in HIV/HCV-Coinfected Individuals

Expert Analysis

HIV Highlights From ICAAC

Faculty:
Joseph J. Eron, Jr., MD Joel E. Gallant, MD, MPH Trevor Hawkins, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of antiretroviral agents
Describe new insights into the management of adverse effects of antiretroviral therapy
Identify the new classes of antiretroviral agents that have been recently approved or are in advanced clinical trials
Discuss the importance of viral tropism in the management of HIV-infected patients

CME CREDIT INFORMATION

Release Date: 11/09/07

Expiration Date: 11/08/08

Physicians: maximum of 1.75 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.7 contact hours (0.17 CEUs)

Registered Nurses: 1.7 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.